

DECLARATION

As the below named inventors, we hereby declare that:

Our residences, post office addresses and citizenships are as stated below next to our names.

We believe that we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled

Method and Device for Treating Scoliosis

the specification of which was filed February 15, 2002 as Serial Number

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims.

We acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56 and in particular information which has occurred between the filing date of our earlier application and the filing date of this application.

We hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior U.S. Application

<u>60/268,860</u>	<u>US</u>	<u>February/16/2001</u>	Priority
(Number)	(Country)	(Month/Day/Year Filed)	<u>Claimed</u>
			[X] []
			Yes No

<u> </u>	<u> </u>	<u> </u>	Priority
(Number)	(Country)	(Month/Day/Year Filed)	<u>Claimed</u>
			[X] []
			Yes No

20051209 10075373.021502

POWER OF ATTORNEY

We hereby appoint Stephen J. Scribner (Reg. No. 44,452) and Carol Miernicki Steeg (Reg. No. 39,539), care of PARTEQ Innovations, Room 1625, Biosciences Complex, Queen's University, Kingston, Ontario K7L 3N6, Canada as our attorney or agent to prosecute this application, to make alterations and amendments therein, to receive the patent and all correspondence relating to this application, and to transact all business in the United States Patent and Trademark Office connected therewith, and the said attorney or agent is hereby given full power of substitution and revocation.

Please address all correspondence concerning this application to Stephen J. Scribner, Parteq Innovations, Room 1625, Biosciences Complex, Queen's University, Kingston, Ontario K7L 3N6, Canada.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first joint inventor: SOBOLESKI, Donald A.

First Inventor's Signature

Dated CA
Citizenship

Site 5, Gp Bx 3, R.R. # 1
Sydenham, Ontario, K0H 2T0
Canada

Residence and Post Office Address

1007537 021502

Second Inventor's Signature

CA
Dated _____ Citizenship _____

Full name of third joint inventor: BORSCHNECK, Daniel P.

Second Inventor's Signature

CA
Dated _____ Citizenship _____

1965 Rosedale Drive
Glenburnie, Ontario, K0H 1S0
Canada

Residence and Post Office Address

Abstract The purpose of this study was to determine the effect of a 10-week, 100-hr, 100-mile, 100-lb. weight loss program on the body composition and physical fitness of 100 obese women. The program was designed to be a total lifestyle change, including diet, exercise, and behavior modification. The program was evaluated using a pretest and posttest design. The pretest was conducted at the beginning of the program, and the posttest was conducted at the end of the program. The results of the study showed that the program was effective in reducing body weight, body fat, and waist circumference. The program also resulted in improvements in physical fitness, including increases in aerobic capacity, muscular strength, and flexibility. The program was well-received by the participants, and the results suggest that it may be a viable option for the treatment of obesity.